<DOC>
	<DOCNO>NCT02392845</DOCNO>
	<brief_summary>To determine maximum tolerate dose densified regimen association docetaxel ( DTX ) epirubicin ( EPI ) , support concomitant administration hematopoietic growth factor patient metastatic breast cancer first-line , optimize patient administration schedule use formal procedure base mathematical model order manage severity induce neutropenia . The model use project allow : - optimal administration schedule plan total dose per cycle ( number infusion calculate rate duration ) - individualization administration schedule second cycle ( base observation first cycle ) , - assessment risk dose-limiting toxicity event combine several severe non-hematological toxicity ( condition decision dose escalation ) . Using formal mathematical model investigator expect control hematological non-hematological toxicity order realize full series six cycle densified DTX+EPI chemotherapy ( 2 week per cycle ) patient . For patient , chemotherapy consider feasible possible , absence tumor progression , consider 6 cycle treatment without observe serious adverse event without : - patient death may relate treatment ; - decision patient interrupt treatment physical psychological tolerance reason ; - decision investigator discontinue treatment , absence disease progression .</brief_summary>
	<brief_title>A Pilot Dose Escalation Trial Densified Chemotherapy Association Docetaxel Epirubicin Driven Mathematical Modeling Metastatic Breast Cancer Patients : The MODEL1 Study</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Age ≥ 18 year , ECOG performance status ≤ 2 Diagnosed metastatic HER2negative hormoneresistant chemotherapynaive breast cancer , previous adjuvant chemotherapy treatment allow . Histologically cytologically proven breast cancer metastasis associate CA 153 level 50 % normal value Hormone resistance define presence negative hormone receptor disease progression within 6 month initiation hormone therapy . Adequate renal liver function ( ASAT ALAT &lt; twice upper limit normal value ( ULN ) liver metastasis , &lt; 4×ULN liver metastasis ; total bilirubin &lt; 2×ULN ) , Adequate cardiac function ( left ventricular ejection fraction ( LVEF ) &gt; 50 % ) , Neutrophils ≥ 1200/mm3 Platelets ≥ 105/mm3 Cerebral metastasis meningeal involvement , Other malignant disease , Significant comorbidities , Previous chemotherapy metastatic disease , previous chemotherapy total cumulative dose great 600 mg/m² EPI great 450 mg/m² DTX</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Drug combination</keyword>
	<keyword>Accelerated chemotherapy</keyword>
	<keyword>Mathematical model</keyword>
	<keyword>Hematotoxicity</keyword>
	<keyword>Individualized dosage</keyword>
</DOC>